Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

The FDA's decision comes despite mixed results in clinical trials of the drug as an adjunctive treatment for depression. It comes on the back of a new pair of pivotal trials (RGH-MD-75 and 3111 ...

TMS of Central Florida, a leading treatment center in Brandon, is offering cutting-edge therapy to help local residents ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...

As researchers and governments consider the therapeutic uses of psychedelics, Scott Marshall stands ready to supply them.

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...